ArticleTherapeutic advances in urology
Endoscopic management of vesicourethral anastomotic stenosis after radical prostatectomy: final outcomes defined by urethral patency and continence.
Article in Therapeutic advances in urology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vesicourethral anastomotic stenosis (VUAS) remains a challenging sequela of radical prostatectomy (RP). Objectives: To evaluate endoscopic outcomes in men with VUAS using a patient-centred composite endpoint of concurrent urethral patency and continence. Design: Retrospective, single-centre consecutive case series. Methods: We analysed 60 consecutive men treated endoscopically for VUAS (2014-2023). Primary endpoints were urethral patency (passage of a 20F catheter at 6-month follow-up) and continence (0-1 pad/day at last follow-up; for men with an artificial urinary sphincter (AUS), assessed after device activation). Secondary endpoints included AUS implantation and complications. Subgroup comparisons by prior pelvic radiotherapy (RTx) were performed using Fisher's exact and Mann-Whitney tests. Results: Median follow-up was 40 months. Patency was achieved in 45/60 (75%). Continence was achieved in 22/60 (36.7%): 5 men remained continent without AUS and 17 became continent after AUS; 4/21 AUS required explant for erosion. Composite success (patency plus continence) occurred in 20/60 (33.3%). Prior RTx was not significantly associated with patency, continence, composite success, or AUS implantation. Three men required urinary diversion for pubic bone fistulation and three were diagnosed with bladder cancer (no AUS implanted). Seventeen patients declined AUS despite persistent stress urinary incontinence. Conclusion: Endoscopic treatment restores urethral patency in most men with post-RP VUAS, but the final patient-centred outcome of simultaneous patency and continence is achieved in one-third. These data may support shared decision-making regarding expectations and staged continence surgery. Trial registration: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.